Cansativa expands medicinal cannabis offering in Germany

Pharmaceutical company Cansativa has announced it now holds a manufacturing and import license for medical cannabis for both of its operating sites in Germany.

The approval makes Cansativa the only pharmaceutical company in Germany to have more than one GMP certified facility as an importer and wholesaler.

The certification, approved within the framework of the German Medicinal Products Act, enables the import and marketing of medical cannabis products from all over the world via Cansativa's two operating sites.

From the approval, Cansativa hopes to control the major phases of the sales process in-house from its own distribution centres in the future. The company believes it will be able to strengthen its supply security through a broad global sourcing approach to provide ill patients with medicinal cannabis.

Benedikt Sons, CEO and founder of Cansativa, said: “Single sourcing of medical cannabis is not a sustainable model for us. The granting of manufacturing and import licenses is an important step towards security of supply. The manufacturing authorisation now enables us to release globally sourced products from our own production facilities.”

"Commonly, people often talk about the existence of a large number of so-called importers in Germany. This is incomplete terminology. In terms of pharmaceutical law, an import in the actual sense always requires a batch release by a GMP-certified domestic manufacturer. In our market segment, there are very few companies besides Cansativa that can meet these requirements. Unlike most of our competitors, we are no longer just trading, we are manufacturing. This milestone allows us to move from being a wholesaler to a pharmaceutical company," added Jakob Sons, general counsel and founder of Cansativa.